Literature DB >> 15084739

Fas-disabling small exocyclic peptide mimetics limit apoptosis by an unexpected mechanism.

Akihiro Hasegawa1, Xin Cheng, Kiichi Kajino, Alan Berezov, Kaoru Murata, Toshinori Nakayama, Hideo Yagita, Ramachandran Murali, Mark I Greene.   

Abstract

Fas ligand- (FasL) mediated apoptosis is an important element of tissue-specific organ damage. We have developed biologically active small exocyclic peptide mimetics that disable apoptotic functions of Fas. The most effective mimetic binds to both its receptor and FasL with comparable affinity. In vitro, the most effective antagonist blocked FasL-induced cytotoxicity completely and specifically. In vivo, the antagonistic mimetic also prevented Concanavilin A (Con A) induced hepatitis, a CD4(+) T cell-mediated animal model of liver injury. Although current approaches prevent Fas receptor signaling by excluding FasL binding to Fas, the small molecule mimetics reported here disable Fas by promoting a defective Fas-FasL receptor complex. This event desensitizes FasL-mediated apoptosis by inhibiting extracellular signal regulated kinase activity and up-regulating NF-kappaB.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15084739      PMCID: PMC404091          DOI: 10.1073/pnas.0401597101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  57 in total

1.  Intrathecal administration of neutralizing antibody against Fas ligand suppresses the progression of experimental autoimmune encephalomyelitis.

Authors:  Y Okuda; S Sakoda; H Fujimura; S Nagata; T Yanagihara; C C Bernard
Journal:  Biochem Biophys Res Commun       Date:  2000-08-18       Impact factor: 3.575

2.  Disabling erbB receptors with rationally designed exocyclic mimetics of antibodies: structure-function analysis.

Authors:  A Berezov; H T Zhang; M I Greene; R Murali
Journal:  J Med Chem       Date:  2001-08-02       Impact factor: 7.446

Review 3.  Death the Fas way: regulation and pathophysiology of CD95 and its ligand.

Authors:  K Sharma; R X Wang; L Y Zhang; D L Yin; X Y Luo; J C Solomon; R F Jiang; K Markos; W Davidson; D W Scott; Y F Shi
Journal:  Pharmacol Ther       Date:  2000-12       Impact factor: 12.310

4.  Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis.

Authors:  H Zhang; J Cook; J Nickel; R Yu; K Stecker; K Myers; N M Dean
Journal:  Nat Biotechnol       Date:  2000-08       Impact factor: 54.908

5.  MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors.

Authors:  S E Tran; T H Holmstrom; M Ahonen; V M Kahari; J E Eriksson
Journal:  J Biol Chem       Date:  2001-01-25       Impact factor: 5.157

6.  Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo.

Authors:  B W Park; H T Zhang; C Wu; A Berezov; X Zhang; R Dua; Q Wang; G Kao; D M O'Rourke; M I Greene; R Murali
Journal:  Nat Biotechnol       Date:  2000-02       Impact factor: 54.908

Review 7.  Non-apoptotic Fas signaling.

Authors:  Harald Wajant; Klaus Pfizenmaier; Peter Scheurich
Journal:  Cytokine Growth Factor Rev       Date:  2003-02       Impact factor: 7.638

Review 8.  Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy.

Authors:  M Fan; T C Chambers
Journal:  Drug Resist Updat       Date:  2001-08       Impact factor: 18.500

9.  Disabling receptor ensembles with rationally designed interface peptidomimetics.

Authors:  Alan Berezov; Jinqiu Chen; Qingdu Liu; Hong-Tao Zhang; Mark I Greene; Ramachandran Murali
Journal:  J Biol Chem       Date:  2002-05-14       Impact factor: 5.157

10.  Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor.

Authors:  F Gantner; M Leist; A W Lohse; P G Germann; G Tiegs
Journal:  Hepatology       Date:  1995-01       Impact factor: 17.425

View more
  9 in total

1.  Disabling TNF receptor signaling by induced conformational perturbation of tryptophan-107.

Authors:  Ramachandran Murali; Xin Cheng; Alan Berezov; Xiulian Du; Arnie Schön; Ernesto Freire; Xiaowei Xu; Youhai H Chen; Mark I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-25       Impact factor: 11.205

2.  Topomimetics of amphipathic beta-sheet and helix-forming bactericidal peptides neutralize lipopolysaccharide endotoxins.

Authors:  Xuemei Chen; Ruud P M Dings; Irina Nesmelova; Stefan Debbert; Judith R Haseman; Jacques Maxwell; Thomas R Hoye; Kevin H Mayo
Journal:  J Med Chem       Date:  2006-12-28       Impact factor: 7.446

Review 3.  Rational Design of Constrained Peptides as Protein Interface Inhibitors.

Authors:  Ramachandran Murali; Hongtao Zhang; Zheng Cai; Lian Lam; Mark Greene
Journal:  Antibodies (Basel)       Date:  2021-08-16

4.  Synthetic disulfide-bridged cyclic peptides mimic the anti-angiogenic actions of chondromodulin-I.

Authors:  Shigenori Miura; Jun Kondo; Toru Kawakami; Chisa Shukunami; Saburo Aimoto; Hideyuki Tanaka; Yuji Hiraki
Journal:  Cancer Sci       Date:  2012-04-27       Impact factor: 6.716

5.  RIPK1 protects hepatocytes from death in Fas-induced hepatitis.

Authors:  Aveline Filliol; Muhammad Farooq; Claire Piquet-Pellorce; Valentine Genet; Marie-Thérèse Dimanche-Boitrel; Peter Vandenabeele; Mathieu J M Bertrand; Michel Samson; Jacques Le Seyec
Journal:  Sci Rep       Date:  2017-08-23       Impact factor: 4.379

Review 6.  Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases.

Authors:  Vesna Risso; Elodie Lafont; Matthieu Le Gallo
Journal:  Cell Death Dis       Date:  2022-03-17       Impact factor: 9.685

7.  Structure based antibody-like peptidomimetics.

Authors:  Ramachandran Murali; Mark I Greene
Journal:  Pharmaceuticals (Basel)       Date:  2012-02-16

8.  p53-independent structure-activity relationships of 3-ring mesogenic compounds' activity as cytotoxic effects against human non-small cell lung cancer lines.

Authors:  Saori Fukushi; Hironori Yoshino; Atsushi Yoshizawa; Ikuo Kashiwakura
Journal:  BMC Cancer       Date:  2016-07-25       Impact factor: 4.430

9.  Intranasal delivery of a Fas-blocking peptide attenuates Fas-mediated apoptosis in brain ischemia.

Authors:  Irfan Ullah; Kunho Chung; Jungju Oh; Jagadish Beloor; Sumin Bae; Sangah Clara Lee; Minhyung Lee; Priti Kumar; Sang-Kyung Lee
Journal:  Sci Rep       Date:  2018-10-09       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.